Synthesis of Diastereomerically Pure Cetrorelix Acetate by Using Fmoc Solid‐Phase Peptide Synthesis (SPPS) Strategy: A Commercially Viable Approach
- 19 May 2025
- journal article
- Published by Wiley in Journal of Peptide Science
- Vol. 31 (6) , e70030
Abstract
In the synthesis of cetrorelix via solid‐phase peptide synthesis (SPPS) employing the Fmoc strategy, the racemization of L‐arginine and L‐serine was effectively minimized to below 0.5%. This reduction was achieved using the coupling agent HATU, the additive HOBt or HOAt, and the base TMP. Racemization was observed during the coupling of Fmoc‐L‐arginine(Pbf) and Fmoc‐O‐tert‐butyl‐L‐serine on Rink Amide AM resin. A gradient reversed‐phase high‐performance liquid chromatography (RP‐HPLC) method was developed for the separation of all the structurally closely related cetrorelix isomers. Optimized RP‐HPLC conditions identified D‐arginine and D‐serine isomeric impurities as the closest eluting peaks to the main cetrorelix peak. Controlling these impurities to the lowest possible levels is essential for developing an efficient preparative HPLC purification process for the commercial production of cetrorelix. This stringent control ensures that the final product meets the high standards required for commercial production and therapeutic use.Keywords
This publication has 15 references indexed in Scilit:
- Characterization of Synthetic Peptide Therapeutics Using Liquid Chromatography–Mass Spectrometry: Challenges, Solutions, Pitfalls, and Future PerspectivesJournal of the American Society for Mass Spectrometry, 2021
- Impurity identification and quantification for arginine vasopressin by liquid chromatography/high‐resolution mass spectrometryRapid Communications in Mass Spectrometry, 2020
- The identification and chromatographic separation of a new highly analogous impurity of the active pharmaceutical ingredient icatibantEuropean Journal of Pharmaceutical Sciences, 2019
- Advances in Fmoc solid‐phase peptide synthesisJournal of Peptide Science, 2016
- Related impurities in peptide medicinesJournal of Pharmaceutical and Biomedical Analysis, 2014
- Cetrorelix, a potent LHRH-antagonist: Chemistry, pharmacology and clinical data2005
- Development and in vitro evaluation of a liposome based implant formulation for the decapeptide cetrorelixEuropean Journal of Pharmaceutics and Biopharmaceutics, 2005
- Racemization of Amino Acids in Solid-Phase Peptide Synthesis Investigated by Capillary ElectrophoresisAnalytical Chemistry, 1996
- Responses to the antagonistic analog of LH-RH (SB-75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancerThe Prostate, 1994
- Racemization1993